SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) March 20, 1997
BIOCONTROL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822 25-1229323
(State of other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (412) 349-1811
_________________________________________________________________
(Former name or former address,
if changes since last report.)
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
On March 20, 1997, Biocontrol Technology, Inc.
(NASDAQ:BICO) announced that Company representatives will address
a Food and Drug Administration Clinical Chemistry and Clinical
Toxicology Devices Panel on Friday, March 21, 1997. The panel
will meet both Thursday and Friday to discuss noninvasive and
invasive self-monitoring glucose systems and related supplies
designed for use by people with diabetes.
Item 6. Resignation of Registrant's Directors.
Not Applicable
Item 7. Financial Statement, Pro Forma Financial Information
and Exhibits.
(a) Financial Statements and Businesses Acquired - Not
Applicable.
(b) Pro Forma Financial Information - Not Applicable.
(c) Exhibits-Press Release
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act
of 1934, the Registrant has duly caused this Report to be signed
on its behalf by the undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s Fred E. Cooper
Fred E. Cooper, CEO
DATED: March 20, 1997
BICO
BIOCONTROL TECHNOLOGY, INC.
2275 Swallow Hill Road, Bldg. 2500
Pittsburgh, PA 15220
Press Release
Release: Immediate
For More Information, Call:
Investors Media
Diane McQuaide
Susan Taylor
1.412.429.0673 phone
1.412.279.9455 phone
1.412.279.9690 fax
1.412.279.9447 fax
BIOCONTROL INVITED TO SPEAK AT FDA PANEL
Pittsburgh, PA - March 20, 1997 - Biocontrol Technology,
Inc.(Nasdaq:BICO) announced today that Company representatives
will address a Food and Drug Administration (FDA) Clinical
Chemistry and Clinical Toxicology Devices Panel on Friday, March
21, 1997. The panel will meet both Thursday and Friday to
discuss noninvasive and invasive self-monitoring glucose systems
and related supplies designed for use by people with diabetes.
Mr. David L. Purdy, president of Biocontrol, will discuss
the noninvasive glucose sensor technology and the manner in which
the Diasensorr 1000 has been designed to reduce patient error and
insure patient safety. With invasive meters, there is
considerable risk of patient procedural error which results in
inaccurate readings of the amount of glucose in the blood. Mr.
Purdy will also explain how the Diasensorr 1000 will initially
work together with the currently used invasive meters to further
ensure the patient's safety.
Biocontrol's Manager of Applications Engineering, Patrick J.
Cooper, Ph.D., is scheduled to address areas where improvement is
possibly needed in the testing and review of new technologies in
general and as they specifically relate to BICO's Diasensorr 1000
noninvasive glucose sensor for diabetics. Dr. Cooper will also
express the opinion that perhaps a technology as new and
different as is used in the Diasensorr 1000 should not be judged
by the same standards used for older, existing technology.
Thomas Pitts, MD, a member of Biocontrol's Medical Advisory
Board, will tell the panel that, as an endocrinologist treating
diabetics, he "believes glucose meters, since their inception,
have had only marginal accuracy. The strength of these meters in
helping manage diabetes has been the review of multiple values
from multiple tests to look at trends and that noninvasive
technology should follow the same lead."
The Company also said that the FDA-requested in-home testing
of its Diasensorr 1000 noninvasive glucose sensor continues as
planned.
Biocontrol Technology, Inc. has its corporate offices in
Pittsburgh, PA and is involved in the development and manufacture
of biomedical devices and environmental products.
